Oxycyte blood substitute shows promise in study:
This article was originally published in Clinica
Synthetic Blood International says that an animal trial of its blood substitute, Oxycyte, has produced positive results. During the study, Oxycyte was used to replace 30% of the circulating blood volume in anaesthetised rats. At a 15-day follow-up, all animals were found to have survived and appeared well, reports the Costa Mesa, California company. Furthermore, despite a 22% drop in haemoglobin concentration, post-transfusion arterial blood oxygenation levels increased by 38%, it adds. The findings support the use of Oxycyte, a perfluorocarbon-based oxygen carrier, in treating blood loss in trauma and surgery in humans, says company president Robert Nicora.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.